Autor(es):Mostrar menos -

Zhang, KeJing ; Wei, Juan ; Zhang, SheYu ; Fei, Liyan ; Guo, Lu ; Liu, Xueying ; Ji, YiShuai ; Chen, WenJun ; Ciamponi, Felipe E. ; Chen, WeiChang ; Li, MengXi ; Zhai, Jie ; Fu, Ting ; Massirer, Katlin B. ; Yu, Yang ; Lupien, Mathieu ; Wei, Yong ; Arrowsmith, Cheryl. H. ; Wu, Qin ; Tan, WeiHong

• Tipo de documento: Artigo Científico
• Fonte: CELL CHEMICAL BIOLOGY; v. 31, n. 11, p. 23-pg., 2024-11-21.

Resumo

Paclitaxel-resistant triple negative breast cancer (TNBC) remains one of the most challenging breast cancers to treat. Here, using an epigenetic chemical probe screen, we uncover an acquired vulnerability of paclitaxelresistant TNBC cells to protein arginine methyltransferases (PRMTs) inhibition. Analysis of cell lines and inhouse clinical samples demonstrates that resistant cells evade paclitaxel killing through stabilizing mitotic chromatin assembly. Genetic or pharmacologic inhibition of PRMT5 alters RNA splicing, particularly intron retention of aurora kinases B (AURKB), leading to a decrease in protein expression, and finally results in selective mitosis catastrophe in paclitaxel-resistant cells. In addition, type I PRMT inhibition synergies with PRMT5 inhibition in suppressing tumor growth of drug-resistant cells through augmenting perturbation of AURKB-mediated mitotic signaling pathway. These findings are fully recapitulated in a patient-derived xenograft (PDX) model generated from a paclitaxel-resistant TNBC patient, providing the rationale for targeting PRMTs in paclitaxel-resistant TNBC. (AU)

• Processo FAPESP: 20/02006-0 - Caracterização molecular e estrutural de proteínas de ligação a RNA como alvos terapêuticos em câncer e neurologia
• Beneficiário: Katlin Brauer Massirer
• Modalidade de apoio: Auxílio à Pesquisa - Parceria para Inovação Tecnológica - PITE